Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma Clinical Trial

Official title:

Multi-target Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine Maintenance Therapy Treating Oligometastatic Nasopharyngeal Carcinoma: a Single-arm, Multicenter, Prospective, Open-label Phase II Clinical Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05290194
• Other study ID #: ZDWY[2022]LunziNo.(K11-1)
• Status: Recruiting
• Phase: Phase 2
• Start date: March 28, 2022
• Est. completion date: January 1, 2027

Study information

• Verified date: April 2022
• Source: Fifth Affiliated Hospital, Sun Yat-Sen University
• Contact: Zhigang MD Liu, PhD
• Phone: 2528888
• Email: zhigangliu1983[@]hotmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single-arm, multicenter, prospective, open-label phase II clinical trial of multi-target radiotherapy combined with PD-1 monoclonal antibody and capecitabine maintenance therapy treating oligometastatic nasopharyngeal carcinoma, the main purpose of which is to evaluate the efficacy of multi-target radiotherapy combined with PD-1 monoclonal antibody and capecitabine maintenance therapy regimen in treating oligometastatic nasopharyngeal carcinoma.

Description:

This is a single-arm, multicenter, prospective, open-label phase II clinical study of multi-target radiotherapy combined with PD-1 monoclonal antibody and capecitabine maintenance therapy for oligometastatic nasopharyngeal carcinoma. Its primary objective is to assess the efficacy, including progression-free survival (PFS), 2-year overall survival (Two-year OS) and progression-free survival (Two-year PFS), overall survival (OS), duration of response (DOR) and safety of multi-target radiotherapy combined with PD-1 monoclonal antibody and capecitabine maintenance therapy in treating oligometastatic nasopharyngeal carcinoma. The secondary objective is to explore the potential genetic biomarkers and clinical therapeutic efficacy evaluation and prediction model of multi-target radiotherapy combined with PD-1 monoclonal antibody and capecitabine maintenance therapy regimen in treating oligometastatic nasopharyngeal carcinoma, providing the evidence of the screening of the potential patients benefiting from the regimen of this trial.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 28
• Est. completion date: January 1, 2027
• Est. primary completion date: December 1, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. The patient was histologically or cytologically diagnosed with nasopharyngeal carcinoma;

2. The patient was newly diagnosed with metastatic nasopharyngeal carcinoma (AJCC eighth edition), and after 4-6 cycles of gemcitabine plus cisplatin combined with PD-1 monoclonal antibody regimen, the efficacy reached more than stable disease;

3. Except for the primary tumor and cervical lymph node metastasis, less than 5 distant organ metastases, and were suitable for SBRT radiotherapy;

4. ECOG PS score 0-2 points;

5. Aged 18-70 years old;

6. Major organ function met the following criteria (14 do not allow the use of any blood components and cell growth factor):

1. Neutrophil ANC = 2.0 × 10^9/L; platelet count PLT = 100 × 10^9/L; hemoglobin HB = 90 g/L;

2. Serum albumin = 28 g/L;

3. Alanine aminotransferase ALT, aspartate aminotransferase AST = 2.5 × ULN; if there is liver metastasis, ALT and AST = 5 × ULN;

4. Serum creatinine = 1.5 × ULN, Or creatinine clearance = 60 mL/min;

5. INR = 1.5 × ULN, and APTT = 1.5 × ULN;

7. Life expectancy = 12 weeks;

8. The subject who voluntarily joins the study, sign informed consent, and coordinates with follow-up.

Exclusion Criteria:

1. Recurrent and metastatic nasopharyngeal carcinoma after initial treatment;

2. Patients received previous treatment of primary lesion or metastasis except for the standard first-line regimen (gemcitabine plus cisplatin combined with PD-1 monoclonal antibody regimen), including induction chemotherapy, adjuvant chemotherapy, concurrent chemoradiotherapy, surgery and other treatments;

3. Central nervous system metastastic (confirmed or suspected);

4. Allergy to PD-1 monoclonal antibody or other PD-1 monoantibody; intolerance or allergy to capecitabine; suffering any disease or extrinsic factors affecting oral drugs;

5. Uncontrolled cardiac clinical symptoms or diseases, such as: ? heart failure of NYHA Grade II or higher ; ? unstable angina pectoris; ? suffering myocardial infarction within 1 year; ? patients with supraventricular or arrhythmia requiring clinical intervention;

6. Severe infection (CTCAE 5.0 = 2) 4 weeks before the first use of study drugs, such as severe pneumonia, bacteremia, infectious complications requiring hospitalization; baseline chest imaging examination suggests the presence of active pulmonary inflammation; symptoms and signs of infection or the need for oral or intravenous antibiotics (excluding the prophylactic use of antibiotics) 2 weeks before the first use of the study drug;

7. History of other malignancies within 5 years or at the time,but except for cured cutaneous basal cell carcinoma and cervical carcinoma in situ, breast carcinoma in situ, superficial bladder tumors (Ta, Tis and T1) and papillary thyroid cancer as well as other cancers treated more than 3 years before the start of the study;

8. Any of the following conditions is met:

1. Received any investigational drug before the first use of the study drug;

2. Participated in another clinical study at the same time, unless it is an observational (non-interventional) clinical study or interventional clinical study at the follow-up time;

3. Required systemic treatments with corticosteroids (the dose higher than the equivalent dose of 10 mg prednisone per day) or other immunosuppressive agents 2 weeks before the first use of the study drug, except for local inflammation and prevention of allergy and nausea and vomiting. In the absence of active autoimmune disease, inhaled or topical steroids and adrenocorticotropic hormone replacement at doses greater than 10 mg daily in prednisone efficacy dose are allowed;

4. Received anti-tumor vaccines or vaccinated live vaccines 4 weeks before the first dose of study drug;

5. Underwent excessive surgery or severe trauma 4 weeks before the first use of study drug;

9. Patients had active autoimmune diseases and a history of autoimmune diseases (such as interstitial pneumonia, colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism, including but not limited to these diseases and syndromes) in the past 2 years; patients who did not require any intervention after adulthood are allowed;

10. History of immunodeficiency, including HIV positive, or other acquired, congenital immunodeficiency diseases, or history of organ transplantation and bone marrow transplantation;

11. Patients with active pulmonary tuberculosis infection found by medical history or CT examination, or with a history of active pulmonary tuberculosis infection within 1 year before enrollment, or with a history of active pulmonary tuberculosis infection 1 year ago but without regular treatment;

12. Patients with active hepatitis (HBV = 2000 IU/ml or HBV DNA = 10000/ml), or hepatitis C (hepatitis C antibody positive, and HCV-RNA = 1000/ml);

13. Patients with coagulation abnormalities (PT > 16s, APTT > 43s, TT > 21s, Fbg < 2 g/L), bleeding tendency or receiving thrombolytic or anticoagulant therapy; or patients with previous severe bleeding (bleeding > 30ml within 3 months), hemoptysis (bleeding > 5ml within 4 weeks) within 12 months due to thromboembolic events (including stroke events and/or transient ischemic attack);

14. Uncontrolled hypertension (systolic blood pressure > 140 mmHg, or diastolic blood pressure > 90 mmHg); coronary heart disease, arrhythmia = grade II (including QTc prolongation, male > 450 ms, female > 470 ms) and heart failure;

15. Urine protein = + +, or 24 hour urine protein = 1.0 g;

16. Current diarrhea-related diseases (e.g., ulcerative colitis, Crohn's disease, chronic diarrhea, etc.);

17. Known history of psychotropic drug abuse, alcoholism and drug abuse; or current history of antiepileptic drug use;

18. Pregnant or lactating;

19. Patients considered unsuitable for inclusion by the investigator as assessed by the investigator.

Related Conditions & MeSH terms

• Capecitabine
• Carcinoma
• Nasopharyngeal Carcinoma
• Radiotherapy

Intervention

Radiation:
• SBRT radiotherapy + Conventionally fractionated radiotherapy
Radiotherapy was performed 3-6 weeks after the end of first-line treatment, followed by conventional fractionated radiotherapy of the primary tumor and cervical lymph node metastases, SBRT radiotherapy of distant organ metastases 3-6 weeks later.

Drug:
• PD-1 inhibitor
Immunotherapy of PD-1 inhibitor is used during the whole time of this trial until subjects were withdrawn from the trial or the trial complete
• Capecitabine
Capecitabine is treated for patients 3-6 weeks after radiotherapy, which combines with PD-1 inhibitor as the maintenance regimen in the trial.

Locations

Country	Name	City	State
China	Fifth Affilliated Hospital of Sun Yat-sen University	Zhuhai	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Fifth Affiliated Hospital, Sun Yat-Sen University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Incidence of Treatment-Emergent Adverse Events	The incidence of adverse events (=Grade 2,CTCAE V5.0)	2 years
Primary	Progress-free survival	The time between enrollment and progression(in any way) or death (for any reason)	2 years
Secondary	Overall survival	Time from randomization to death (for any reason)	2years
Secondary	Duration of response	Time from the first evaluation of the tumor as CR or PR to the first evaluation as PD or death from any cause	2 yaers